Neurology

Doctors and biopharma executives discussed the opportunities and challenges for researching and administering combination therapy at the Clinical Trials on Alzheimer’s Disease meeting.

Novo Nordisk presented topline results from its Phase III semaglutide studies at the Clinical Trials on Alzheimer’s Disease meeting, Lilly SVP Ronald DeMattos advocated for anti-amyloid brain shuttles to reduce ARIA and Eisai presented subcutaneous Leqembi data.

At the Clinical Trials On Alzheimer’s Disease meeting, Novo explained why it tested semaglutide in AD a day before the company’s Phase III EVOKE/EVOKE+ presentation, Roche updated Phase Ib/IIa results for its anti-amyloid trontinemab and UCB’s bepranemab remains in limbo.

Johnson & Johnson said its microtubule binding region (MTBR)-targeting candidate posdinemab did not slow cognitive decline in early Alzheimer’s disease in the Phase II Autonomy trial, marking another setback as anti-tau agents continue to deliver mixed results.

Meg Alexander is taking the place of founder Jeremy Levin, who is transitioning to executive chair, as Ovid prepares to move lead drug OV329 into a Phase IIa epilepsy study and generate initial data for its first-in-class KCC2 direct activators.

Lupin’s US launch of its long-acting risperidone marks the first commercial use of Nanomi’s PrecisionSphere platform, validating a decade-long bet on complex injectables.

The drugmaker increased its offer to $21 per share – equal to Lundbeck’s counteroffer – with the same $1.50 CVR tied to Lumryz’s approval, which Avadel called superior.

Brain-computer interfaces advance toward trials and commercialization, Oura pushes for FDA-cleared blood pressure monitoring, and regulators weigh AI’s expanding role in mental health and diagnostics amid rising safety concerns.

Teva is continuing to decide whether to speed up the FDA review time for its proposed long-acting olanzapine injectable, though the company has numerous options for deploying its priority review voucher across a busy late-stage pipeline.

The Danish drugmaker is offering more per share in cash and CVRs than Alkermes did in the deal announced in October.

The drugmaker plans to move into Phase III development of the drug, which has now posted positive Phase II results in narcolepsy types 1 and 2.

The EMA has scheduled oral explanation meetings this week for Anavex’s blarcamesine and three other products that are nearing the end of the regulatory review cycle. These meetings usually represent the final chance for sponsors to persuade the agency that their product merits approval.